肠道菌群
法尼甾体X受体
肝损伤
胆汁酸
药品
医学
药物代谢
肝病
脂肪肝
肠道通透性
平衡
药理学
生物
内科学
疾病
免疫学
核受体
生物化学
基因
转录因子
作者
Wenjing Tao,Qiwen Fan,Jintao Wei
摘要
Drug-induced liver injury (DILI) is a liver disease that remains difficult to predict and diagnose, and the underlying mechanisms are yet to be fully clarified. The gut-liver axis refers to the reciprocal interactions between the gut and the liver, and its homeostasis plays a prominent role in maintaining liver health. It has been recently reported that patients and animals with DILI have a disrupted gut-liver axis, involving altered gut microbiota composition, increased intestinal permeability and lipopolysaccharide translocation, decreased short-chain fatty acids production, and impaired bile acid metabolism homeostasis. The present review will summarize the evidence from both clinical and preclinical studies about the role of the gut-liver axis in the pathogenesis of DILI. Moreover, we will focus attention on the potential therapeutic strategies for DILI based on improving gut-liver axis function, including herbs and phytochemicals, probiotics, fecal microbial transplantation, postbiotics, bile acids, and Farnesoid X receptor agonists.
科研通智能强力驱动
Strongly Powered by AbleSci AI